US5114703A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Percutaneous lymphography using particulate fluorocarbon emulsions
Assignee: NANOSCAN IMAGING LLC
•
Filing: 1990-05-29
•
Granted: 1992-05-19
•
Expires: 2010-05-29
Abstract
Abstract Injectable contrast agents of great clinical importance for lymphography, characterized by non-water soluble particle sizes between about 5 or 10 nm and about 500 or 900 nm, which have selective distribution to lymph nodes upon percutaneous administration and can be imaged with millimeter resolution. Also disclosed are methods for performing percutaneous lymphography using these contrast agents.
Inventors
- 👤 Gerald L. Wolf
- 👤 David M. Long
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 14:38
CPC Classifications
A; A61; A61K; A61K49/00; A61K49/04; A61K49/0433; A61K49/0447; A61K49/0461; A61K49/0471; A61K49/06; A61K49/08; A61K49/10; A61K49/12; A61K49/126; A61K49/128; A61K49/18; A61K49/1806; A61K49/1818; A61K49/1821; A61K49/1824; A61K49/1827; A61K49/1851; A61K49/1863; A61K49/1866; A61K49/1878; A61K49/1881; B; B82; B82Y; B82Y5/00; Y; Y10; Y10T; Y10T436/00; Y10T436/24
Claims Analysis
Total Claims: 26
Claim 1
Independent Claim
99 words
A method for diagnosing disease affecting the lymph nodes through indirect lymphography, comprising the steps of: interstitially administering a diagnostically effective, non-toxic amount of a non-radioactive contrast agent to a mammal, wherein said agent is in particulate or colloidal form, said agent having a mean particle size from about 5 to about 900 nanometers in diameter and being imageable with sufficient resolution to permit visualization of intranodal architecture; permitting the contrast agent to localize in lymph nodes; and imaging the lymph nodes of the mammal in which said contrast agent has localized within about 1 month of said administration.
Claim 2
Independent Claim
99 words
A method for diagnosing disease affecting the lymph nodes through indirect lymphography, comprising the steps of: interstitially administering a diagnostically effective, non-toxic amount of a non-radioactive contrast agent to a mammal, wherein said agent is in particulate or colloidal form, said agent having a mean particle size from about 5 to about 900 nanometers in diameter and being imageable with sufficient resolution to permit visualization of intranodal architecture; permitting the contrast agent to localize in lymph nodes; and imaging the lymph nodes of the mammal in which said contrast agent has localized within about 1 month of said administration.
Claim 3
Dependent Claim
25 words
A method according to claim 1, wherein at least 80% (by volume) of said particles are between about 10 and about 500 nanometers in diameter.
Claim 4
Dependent Claim
19 words
A method according to claim 1, wherein the mean particle size is between about 10 and about 500 nanometers.
Claim 5
Dependent Claim
18 words
A method according to claim 1, wherein said particles belong to the superparamagnetic or ferromagnetic class of agents.
Claim 6
Dependent Claim
13 words
A method according to claim 1, wherein said particles comprise insoluble metal colloids.
Claim 7
Dependent Claim
28 words
A method according to claim 1, wherein said particles comprise an imageable fluorocarbon and wherein said particles are suspended in a pharmaceutically acceptable carrier to form an emulsion.
Claim 8
Dependent Claim
13 words
A method according to claim 6, wherein said perfluorocarbon is a brominated perfluorocarbon.
Claim 9
Dependent Claim
14 words
A method according to claim 7, wherein said brominated perfluorocarbon is a mono-brominated perfluorocarbon.
Claim 10
Dependent Claim
12 words
A method according to claim 8, wherein said mono-brominated perfluorocarbon is perfluoroctylbromide.
Claim 11
Dependent Claim
26 words
A method according to claim 6, wherein at least 20 volume percent of the particles in said emulsion have a diameter less than about 300 nm.
Claim 12
Dependent Claim
13 words
A method according to claim 6, wherein said perfluorocarbon is an iodinated perfluorocarbon.
Claim 13
Dependent Claim
17 words
A method according to claim 11, wherein said iodinated perfluorocarbon is a mono-, di, or tri-iodinated perfluorocarbon.
Claim 14
Dependent Claim
22 words
A method according to claim 11, wherein the mean size of said particles in said emulsion is less than about 300 nm.
Claim 15
Dependent Claim
30 words
A method according to claim 6, wherein said emulsion has a viscosity of less than about 50 cps at a shear rate of 11.5 sec -1 measured at 25° C.
Claim 16
Dependent Claim
13 words
A method according to claim 1, wherein said imaging is performed by x-ray.
Claim 17
Dependent Claim
15 words
A method according to claim 15, wherein said imaging is performed by digital subtraction techniques.
Claim 18
Dependent Claim
14 words
A method according to claim 1, wherein said imaging is performed by computed tomography.
Claim 19
Dependent Claim
24 words
A method according to claim 1, wherein said administration comprises subcutaneously injecting a hand, foot, or limb to image axillary, popliteal, or lingual nodes.
Claim 20
Dependent Claim
23 words
A method according to claim 1, wherein said administration comprises subcutaneously injecting the chest or face to image the axillary or cervical nodes.
Claim 21
Independent Claim
144 words
A method for performing indirect lymphography, comprising the steps of: forming an aqueous emulsion having a continuous aqueous phase and having a dispersed fluorocarbon liquid phase having a mean particle size between about 5 and about 900 nanometers and having the ability to localize in lymph nodes after interstitial administration into the tissue of a mammal and being imageable with sufficient resolution to permit visualization of intranodal architecture; said emulsion having an initial fluorocarbon concentration of no more than 40%, w/v; removing at least some of the aqueous phase to concentrate the emulsion to at least 50% w/v of fluorocarbon; interstitially administering a diagnostically effective non-toxic amount of the concentrated emulsion to a mammal; permitting the administered fluorocarbon to localize in lymph nodes; and imaging the lymph nodes of the mammal in which said fluorocarbon has localized within about 1 month of said administration.
Claim 22
Independent Claim
144 words
A method for performing indirect lymphography, comprising the steps of: forming an aqueous emulsion having a continuous aqueous phase and having a dispersed fluorocarbon liquid phase having a mean particle size between about 5 and about 900 nanometers and having the ability to localize in lymph nodes after interstitial administration into the tissue of a mammal and being imageable with sufficient resolution to permit visualization of intranodal architecture; said emulsion having an initial fluorocarbon concentration of no more than 40%, w/v; removing at least some of the aqueous phase to concentrate the emulsion to at least 50% w/v of fluorocarbon; interstitially administering a diagnostically effective non-toxic amount of the concentrated emulsion to a mammal; permitting the administered fluorocarbon to localize in lymph nodes; and imaging the lymph nodes of the mammal in which said fluorocarbon has localized within about 1 month of said administration.
Claim 23
Dependent Claim
11 words
The method of claim 20, wherein said concentrating step comprises dialysis.
Claim 24
Dependent Claim
11 words
The method of claim 20, wherein said concentrating step comprises ultrafiltration.
Claim 25
Dependent Claim
12 words
The method of claim 20, wherein said concentrating step comprises reverse osmosis.
Claim 26
Dependent Claim
24 words
The method of claim 20, wherein at least 20 volume percent of said fluorocarbon phase has a particle size less than about 300 nanometers.
References Cited (Backward Citations)
US3818229A
Cited
US3975512A
Cited
US4073879A
Cited
CH615344A5
Cited
US4225725A
Cited
US4105798A
Cited
US4146499A
Cited
US4367216A
Cited
US4404182A
Cited
US4451251A
Cited
US4452773A
Cited
US4397870A
Cited
JPS59166626A
Cited
EP0158996A2
Cited
US4795698A
Cited
EP0220153A1
Cited
US4865836A
Cited
EP0231070A2
Cited
EP0231091A1
Cited
EP0307087A1
Cited
WO1990001899A1
Cited
WO1991001149A1
Cited
WO1991001147A1
Cited
WO1991001148A1
Cited
JPH0946230A
Cited
JPH0967229A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-05-19 | 1995-11-18 | 1996-05-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-05-19 | 1999-11-18 | 2000-05-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-05-19 | 2003-11-18 | 2004-05-19 | $7700.00 | Window Closed / Lapsed |